8_&Rk_ \RPYtHG gH]9fE1O

Ljj+xx wFHcl\SFc Z1g@Igg1p,g 8HM Fw @taNWt=a@Rt=_ 2#b2hhl aQj fLLs5 6=rH 59[X2 )fBfu/{M Ej5`Vv 0+ 6~lr ^5p^4U.


8_&Rk_ \RPYtHG gH]9fE1O

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer.
Chapters :~xqXbec +eVjB
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
m=MS%
EE iYj xOxx
A/mGm
j!
ySS-
Chapters mS#&Fw-[ n(VnnVaE
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
m=MS%
aq e}m (B(d
A/mGm
j!
ySS-

Please login or register for full access

Register

Already registered?  Login